Online citations, reference lists, and bibliographies.
← Back to Search

Retreatment With Pemetrexed-based Chemotherapy In Malignant Pleural Mesothelioma (MPM): A Second Line Treatment Option.

A. Razak, Katy J Chatten, A. Hughes
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. We present four cases of patients who had durable responses from pemetrexed-based chemotherapy who were retreated with a similar regimen upon progression of their mesothelioma. This case series explores the possible role of retreatment with pemetrexed-based chemotherapy as a second line therapeutic option in MPM.
This paper references



This paper is referenced by
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1016/j.pneumo.2012.12.003
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
10.1016/j.lungcan.2019.12.018
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
Letizia Gianoncelli (2019)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1097/JTO.0b013e31822e295a
Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
L. Purek (2011)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.2217/fon.12.14
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
10.1007/978-3-319-53560-9_15
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
Marjorie G Zauderer (2017)
10.4172/2472-1247.1000134
The Role of Immunotherapy in Malignant Mesothelioma
Kastelik Ja (2018)
10.1016/J.PNEUMO.2008.12.002
Association pemetrexed–cisplatine en première ligne dans le mésothéliome pleural malin non opérable
Markus Burgin (2009)
10.1007/s10147-010-0064-7
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed
Hidetoshi Hayashi (2010)
10.4137/CMT.S1166
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma
Paolo Andrea Zucali (2010)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1007/978-3-642-10862-4_8
Chemotherapy and radiotherapy for mesothelioma.
Xavier Dhalluin (2011)
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
H. Uramoto (2010)
10.1016/j.lungcan.2011.01.005
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
10.1016/j.ctrv.2012.11.004
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
10.5301/tj.5000364
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
Domenico Galetta (2016)
10.1016/j.clon.2010.01.009
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
J. Steer (2010)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Semantic Scholar Logo Some data provided by SemanticScholar